Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Madrigal Pharmaceuticals gains FDA approval for NASH medicine Rezdiffra

Madrigal Pharmaceuticals achieved FDA approval for Rezdiffra, focusing on market leadership and patient services.
Sales expected to be back-end loaded in 2024, with varying prescription dynamics and affordability considerations.
Company confident in revenue consensus but hasn't provided specific numbers, creating uncertainty for investors.
Emphasis on high unmet need, early positive feedback, and comprehensive patient support services.

Madrigal Pharmaceuticals excels in Q2 with Rezdiffra launch success

Madrigal Pharmaceuticals demonstrated strong financial performance and market acceptance of Rezdiffra in Q2 2024.
The company faces challenges in educating stakeholders and managing operational aspects of expansion.
Opportunities lie in global expansion, new market segments, and continued growth in sales and brand recognition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on March 2000 and is headquartered in West Conshohocken, PA.

Biotech bulls stampeded the company following its latest clinical update.

Why Madrigal Pharmaceuticals Was a Top Stock This Week

Bionano Genomics

GlaxoSmithKline

iCAD

Schrodinger 

Verona Pharma

vTv Therapeutics

Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves in clinical trials.

7 Drug Stocks That Will Soar in 2023

CONSHOHOCKEN, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that it has raised $259 million in gross equity (or $255 million in net proceeds) from equity securities issuances and an additional $50 million in liquidity commitments following the achievement of the clinical milestone under its Hercules Credit Facility.

Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program

On Monday, Madrigal Pharmaceuticals announced a best-case dataset from its phase 3 trial in NASH. This opens up a Huge market for the company.

Madrigal: Next Steps After 'Wow' Data In NASH

Madrigal Pharmaceuticals announced positive top-line results from their phase three trial evaluating Resmetirom as a treatment for NASH fibrosis on Monday, sending shares up by almost 300 percent since. Both the 80 milligram and 100 milligram dosages achieved statistical significance over placebo for both primary endpoints — fibrotic reduction and NASH resolution.

Madrigal Pharmaceuticals Is Still Undervalued After Resmetirom's Phase 3 Success

Madrigal's (MDGL) phase III MAESTRO-NASH study evaluating resmetirom for treating nonalcoholic steatohepatitis and liver fibrosis meets both primary endpoints. Stock rises.

Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study

Madrigal Pharmaceuticals Inc  (NASDAQ:MDGL) is surging, last seen up 250.3% to trade at $223.50, after its experimental drug Resmetirom met the main goals of a late-stage study.

Madrigal's Successful Late-Stage Trial Draws Options Bulls

The company reported stellar late-stage clinical trial results for its experimental NASH (nonalcoholic steatohepatitis) drug.

Why Madrigal Pharmaceuticals Stock Is Crushing It Today

Madrigal Pharmaceuticals announced positive results for a major clinical trial and shares are up more than 200% because of it.

Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) shares have soared more than 250% after the biopharmaceutical company shared positive topline results from its pivotal Phase 3 MAESTRO-NASH biopsy clinical trial of resmetirom, a liver-directed selective thyroid hormone receptor agonist.  The company, which is pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), said that resmetirom achieved both primary endpoints and potentially clinically meaningful effects with both daily oral doses 80mg and 100mg relative to placebo in the 52-week serial biopsy trial of more than 950 patients.

Madrigal Pharmaceuticals shares soar on positive trial results for its NASH and liver fibrosis drug resmetirom

Tesla

Tesla's Bouncing, but This Nasdaq Stock Tripled Monday Morning

Madrigal Pharmaceuticals (NASDAQ: MDGL ) stock is rocketing higher on Monday after sharing results from its novel therapeutics for nonalcoholic steatohepatitis (NASH) treatment. The company reported positive topline results, including both liver histological improvement endpoints, proposed by the U.S. Food and Drug Administration (FDA).

Why Is Madrigal Pharmaceuticals (MDGL) Stock Up 216% Today?

Madrigal scored a win in the particularly tricky NASH field on Monday after its study hit both its goals, sending MDGL stock flying. The post Madrigal Pharma Stock Triples After Knocking NASH Study Out Of The Park appeared first on Investor's Business Daily.

Madrigal Pharma Stock Triples After Knocking NASH Study Out Of The Park

The stock price of Madrigal Pharmaceuticals (MDGL) skyrocketed over 200% pre-market today. This is why.

Why The Madrigal Pharmaceuticals (MDGL) Stock Skyrocketed Over 200%

Shares of Madrigal Pharmaceuticals Inc. MDGL, +1.43% soared 209.6% in premarket trading on Monday after the company shared positive data from a pivotal Phase 3 clinical trial assessing its experimental treatment for nonalcoholic steatohepatitis (NASH) with liver fibrosis. Madrigal said it is aiming to get an accelerated approval for the drug, resmetirom.

Madrigal's stock rallies about 200% after sharing positive data about its NASH treatment candidate

CONSHOHOCKEN, Pa., Dec. 18, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), plans to announce topline results from the Phase 3 MAESTRO-NASH study of resmetirom on Monday, December 19th, 2022.

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th

The recent Phase 3 (MAESTRO-NAFLD-1) study delivered extremely strong results. This month, Madrigal is expected to release the data for its Phase 3 (MAESTRO-NASH) trial.

Madrigal: Binary Catalyst Unlocking

Axsome Therapeutics

These two healthcare stocks could deliver market-crushing gains by year's end.

2 Healthcare Stocks Poised to Rocket Higher in the 4th Quarter

CONSHOHOCKEN, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides an overview of upcoming resmetirom Phase 3 data presentations and reports third quarter 2022 financial results.

Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results

The biopsy readout for the pivotal MAESTRO-NASH study on lead product candidate resmetirom is slated for Q4. Many expect a successful trial based on positive Phase 2 data.

Madrigal Pharmaceuticals Forecast: Not So Clear

CONSHOHOCKEN, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 9:30 am ET.

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Madrigal will have a key catalytic event in Q4. This is the data from the ~900 patient subpart H population of biopsy-proven NASH patients.

Madrigal: Buy And Hoard Before Q4 Data Readout

CONSHOHOCKEN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of recent corporate accomplishments and reports its second quarter 2022 financial results.

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results

Fate Therapeutics

IVERIC bio Inc

Karuna Therapeutics Inc

Nkarta, Inc.

Seagen

Takeda Pharmaceutical

One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration approval. If that happens, Jefferies analyst Chris Howerton believes the treatment should have “no issue” topping annual sales of $1 billion, reported BioPharma Dive.

Trial Results Set to Make or Break Small-Cap Pharma Stocks

Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver's International Liver Congress. The data included new details on changes in FibroScan controlled attenuation parameter and liver stiffness.

News for Madrigal Pharmaceuticals Stock (MDGL)